Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative bioavailability and interaction study of dispersible dolutegravir with emtricitabine/tenofovir alafenamide
NL-OMON51616Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dolutegravir, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Radboud University Medical Center. Started Nov 2022; status: active, not recruiting.
02
Drugs
dolutegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON51616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51616.